With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, cardiovascular metabolic diseases among their targets.

GREENE SHEPHERD, PHARM.D., DABAT, is Clinical Associate Professor, Medical College of Georgia, 1120 15th Street, CJ-1020, Augusta, GA 30912-2450 ([email protected]). Copyright © 2006, American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/06/1001-1828$06.00. DOI 10.2146/ajhp060041 Overdoses with cardiovascular drugs are associated with significant morbidity and morta...